People around the globe suffer from a myriad of rare diseases, many of which have no cure or limited treatment options. Many patients have been living without hope of a significant improvement in ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer that often kills within a year of diagnosis. DIPG occurs in an area of the brainstem called the pons, which controls many of ...

The ability to make synthetic DNA and RNA by chemical or enzymatic means has revolutionized genetic research and drug discovery. Antisense technology employs short, chemically synthesized ...

Antisense has been harmed by irresponsible extrapolations and irresponsible overgeneralizations. We saw the beginning of responsible behavior in antisense technology at that meeting, and it was ...

“Antisense” drugs that aim to shut down disease-related genes have long been out of favor, and these days live in the shadow of a hotter and newer technology — RNA interference — that does much the ...

CARLSBAD, Calif., Oct. 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that the first patients have been dosed with ION541 ...

AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the ...

For decades, antisense technology promised to transform the pharmaceutical industry. That moment has now arrived. Dr. Stanley Crooke, a pioneer in the field, explains what’s next. This article was ...

At first, researchers thought that antisense drugs would prove so specific there would be few side effects. But toxicity-related problems did arise in initial animal studies of antisense drugs in the ...

Among the human body’s many maladies, few have stumped medical researchers like those that decimate the brain. After decades of effort, effectively treating—let alone curing—neurodegenerative ...

Economic Moat Ionis has proprietary antisense oligonucleotide technology that has led to three approved RNA-based drugs and a steadily growing pipeline, which together support the firm's intangible ...